PMID- 23499266
OWN - NLM
STAT- MEDLINE
DCOM- 20140218
LR  - 20211203
IS  - 1532-3080 (Electronic)
IS  - 0960-9776 (Linking)
VI  - 22
IP  - 4
DP  - 2013 Aug
TI  - Everolimus in hormone receptor-positive advanced breast cancer: targeting 
      receptor-based mechanisms of resistance.
PG  - 405-10
LID - S0960-9776(13)00034-9 [pii]
LID - 10.1016/j.breast.2013.02.003 [doi]
AB  - Although patients with hormone receptor (HR)-positive breast cancer are 
      successfully treated with endocrine therapy, many tumors go on to develop 
      resistance to these agents. Studies have determined that mechanisms of resistance 
      to endocrine therapy are quite complex and can involve a multitude of signal 
      transduction pathways, either through direct association with the estrogen 
      receptor or through cross-talk with other pathways. Preclinical studies have 
      suggested the therapeutic importance of the mammalian target of rapamycin (mTOR) 
      pathway and that inhibiting this pathway may restore sensitivity to endocrine 
      therapy. The oral mTOR inhibitor everolimus has been extensively studied for 
      breast cancer. Clinical studies suggest that everolimus in combination with 
      endocrine therapy improves progression-free survival and is well tolerated. A 
      combined approach, targeting both mTOR signal transduction and the HR pathways, 
      promises to take clinical research in a new direction for the treatment of 
      HR-positive advanced breast cancer.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
FAU - Shtivelband, Mikhail I
AU  - Shtivelband MI
AD  - Ironwood Cancer & Research Centers, 695 South Dobson Road, Chandler, AZ 85224, 
      USA. MShtivelband@ironwoodcrc.com
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130314
PL  - Netherlands
TA  - Breast
JT  - Breast (Edinburgh, Scotland)
JID - 9213011
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Antineoplastic Agents/*administration & dosage
MH  - Antineoplastic Agents, Hormonal/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/metabolism
MH  - Carcinoma/*drug therapy/metabolism
MH  - *Drug Resistance, Neoplasm
MH  - Everolimus
MH  - Female
MH  - Humans
MH  - Receptor, ErbB-2/metabolism
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, Progesterone/metabolism
MH  - Signal Transduction/drug effects
MH  - Sirolimus/administration & dosage/*analogs & derivatives
MH  - TOR Serine-Threonine Kinases/drug effects
MH  - Tamoxifen/administration & dosage
MH  - Treatment Outcome
EDAT- 2013/03/19 06:00
MHDA- 2014/02/19 06:00
CRDT- 2013/03/19 06:00
PHST- 2012/03/23 00:00 [received]
PHST- 2013/01/15 00:00 [revised]
PHST- 2013/02/11 00:00 [accepted]
PHST- 2013/03/19 06:00 [entrez]
PHST- 2013/03/19 06:00 [pubmed]
PHST- 2014/02/19 06:00 [medline]
AID - S0960-9776(13)00034-9 [pii]
AID - 10.1016/j.breast.2013.02.003 [doi]
PST - ppublish
SO  - Breast. 2013 Aug;22(4):405-10. doi: 10.1016/j.breast.2013.02.003. Epub 2013 Mar 
      14.